StreetInsider.com News Articles

Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Mon, 20 Jul 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces today that Sibnayal® (a prolonged-release combination of potassium citrate and potassium bicarbonate) is now reimbursed in Spain for the treatment of distal Renal Tubular Acidosis (dRTA).

The reimbursed prices of Sibnayal® in Spain are:

- €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg
- €136.62 including tax for Sibnayal® 8 mEq 282 mg/527 mg

Since its approval, Sibnayal® is available to Spanish patients through an early access

Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Mon, 20 Jul 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

The reimbursed prices of Sibnayal® in Spain are:

- €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg
- €136.62 including tax for Sibnayal® 8 mEq 282 mg/527 mg

Since its approval, Sibnayal® is available to Spanish patients through an early access

Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Mon, 20 Jul 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

The reimbursed prices of Sibnayal® in Spain are:

- €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg
- €136.62 including tax for Sibnayal® 8 mEq 282 mg/527 mg

Since its approval, Sibnayal® is available to Spanish patients through an early access

Advicenne Announces the Reimbursement of Sibnayal® for the Treatment of dRTA in Spain

Mon, 20 Jul 2026 12:00:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

The reimbursed prices of Sibnayal® in Spain are:

- €409.84 including tax for Sibnayal® 24 mEq 847mg/1582 mg
- €136.62 including tax for Sibnayal® 8 mEq 282 mg/527 mg

Since its approval, Sibnayal® is available to Spanish patients through an early access

Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France

Thu, 16 Jul 2026 12:35:00 -0400

The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne S.A. (“Advicenne” or the “Company”) (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, today announces its net revenue for the first half of 2026,

Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France

Thu, 16 Jul 2026 12:35:00 -0400

The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France

Thu, 16 Jul 2026 12:35:00 -0400

The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne: Net Revenue for the First Half of 2026 Driven by Reimbursement of Sibnayal® and Likozam® in France

Thu, 16 Jul 2026 12:35:00 -0400

The first half 2026 reported revenue is the first without the negative impact of early access rebates
Reported revenue does not include royalties to be received from commercial partners on Sibnayal® sales
In the French market alone, Sibnayal® sales grew by 41% in volume
Reimbursement of Likozam® has high impact on its sales growth

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne S.A. (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announces the unlimited renewal of the Marketing Authorization (MA) for Sibnayal® (a fixed-dose combination of potassium citrate and potassium bicarbonate) for the treatment of distal Renal Tubular Acidosis (dRTA) in the United Kingdom.

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted the unlimited renewal of MA for Sibnayal® effective June 2026. This renewal, which is mandatory five years after the initial grant, definitively validates the

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Announces the Unlimited Renewal of the Marketing Authorization for Sibnayal® in the United Kingdom

Wed, 01 Jul 2026 11:46:00 -0400

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

Mon, 01 Jun 2026 01:45:00 -0400

Likozam® will be reimbursed to patients starting June 12, 2026
Official reimbursement ends the “Early Access” clawback
The price obtained offsets the discounts owed under the early access program and reduces the debt owed to the French government by nearly €6 million

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.

The price of Likozam® in France,

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

Mon, 01 Jun 2026 01:45:00 -0400

Likozam® will be reimbursed to patients starting June 12, 2026
Official reimbursement ends the “Early Access” clawback
The price obtained offsets the discounts owed under the early access program and reduces the debt owed to the French government by nearly €6 million

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.

The price of Likozam® in France,

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

Mon, 01 Jun 2026 01:45:00 -0400

Likozam® will be reimbursed to patients starting June 12, 2026
Official reimbursement ends the “Early Access” clawback
The price obtained offsets the discounts owed under the early access program and reduces the debt owed to the French government by nearly €6 million

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.

The price of Likozam® in France,

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

Mon, 01 Jun 2026 01:45:00 -0400

Likozam® will be reimbursed to patients starting June 12, 2026
Official reimbursement ends the “Early Access” clawback
The price obtained offsets the discounts owed under the early access program and reduces the debt owed to the French government by nearly €6 million

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.

The price of Likozam® in France,

Advicenne Granted Reimbursement for Likozam® in France and Sees Thereby Its Debt Reduced by Nearly €6 Million

Mon, 01 Jun 2026 01:45:00 -0400

Likozam® will be reimbursed to patients starting June 12, 2026
Official reimbursement ends the “Early Access” clawback
The price obtained offsets the discounts owed under the early access program and reduces the debt owed to the French government by nearly €6 million

PARIS--(BUSINESS WIRE)-- Regulatory News:

Advicenne (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced today that Likozam® (clobazam) is reimbursed by the French social security system, notably for the combination treatment of drug-resistant epilepsy.

The price of Likozam® in France,